Science Advances

advances.sciencemag.org/cgi/content/full/5/8/eaaw3538/DC1

Supplementary Materials for

Genotype-by-environment interactions inferred from genetic effects on phenotypic variability in the UK Biobank

Huanwei Wang, Futao Zhang, Jian Zeng, Yang Wu, Kathryn E. Kemper, Angli Xue, Min Zhang, Joseph E. Powell, Michael E. Goddard, Naomi R. Wray, Peter M. Visscher, Allan F. McRae, Jian Yang*

*Corresponding author. Email: jian.yang.qt@gmail.com

Published 14 August 2019, *Sci. Adv.* **5**, eaaw3538 (2019) DOI: 10.1126/sciadv.aaw3538

This PDF file includes:

Note S1. Theoretical derivation of vQTL as a consequence of GEI

Note S2. The Bartlett's test, the FK test, and the DGLM test

Note S3. Rank-based inverse-normal transformation

Note S4. The effective number of independent traits

Note S5. Definitions of the three environmental factors—PA, SB, and smoking

Note S6. Expected inflation in the Levene's test statistic due to phantom vQTL effect

Note S7. Acknowledgments

Fig. S1. Evaluation of statistical methods and phenotype processing strategies for the vQTL analysis by simulation based on a single-SNP model.

Fig. S2. Phenotypic correlations among 13 quantitative traits, and PA and SB measures in the UKB.

Fig. S3. Genome-wide vQTL and QTL analyses for 13 traits in the UKB.

Fig. S4. Quantile-quantile plots of vQTL associations for the 13 UKB traits.

Fig. S5. Enrichment of GEI effects among the 75 vQTLs compared with a random set of QTLs using the raw phenotypic values.

Fig. S6. Comparison of the Young et al. method with the Levene's test by vQTL simulation.

Fig. S7. Excluding two alternative explanations for vQTL signals: Phantom vQTLs and epistasis. Table S1. Descriptive summary of (A) the quantitative traits and (B) the environmental data used in this study from the UKB.

Table S2. Seventy-five experiment-wise significant vQTLs for nine UKB traits.

Table S3. GEI examples.

References (68–75)

Supplementary Notes

Note S1. Theoretical derivation of vQTL as a consequence of GEI

It has been shown by Pare et al.¹⁷ that the interaction of a genetic variant with a genetic or environmental factor for a trait (e.g., GEI) can lead to differences in variance of the trait across genotype classes of the variant. Take GEI as an example. Under a GEI model, a phenotype y is affected by a genetic variant x_g , an environmental factor x_E , and an interaction term $x_g x_{E,}$, i.e.

$$y = \mu + \beta_g x_g + \beta_E x_E + \beta_{gE} x_g x_E + e$$

where μ is the intercept term, β_g , β_E , β_{gE} are the effects of x_g , x_E and $x_g x_E$, respectively, and e is the residual. The phenotypic variance conditional on the genotype of the variant is

$$Var(y|x_g) = Var(\mu + \beta_g x_g + \beta_E x_E + \beta_{gE} x_g x_E + e)$$
$$= Var((\beta_E + \beta_{gE} x_g) x_E + \mu + \beta_g x_g + e)$$
$$= (\beta_E + \beta_{gE} x_g)^2 Var(x_E) + Var(e)$$

assuming that x_g , x_E and e are independent of each other. This equation shows that the phenotypic variance given a genotype is dependent on the genotype in the presence of GEI (i.e., $\beta_{gE} \neq 0$).

Note S2. The Bartlett's test, the FK test, and the DGLM test

We evaluated four variance quantitative trait locus (vQTL) methods by simulation. Details of the Levene's test have been described in the Methods section of the main text, and details of the other three methods are described below.

The Bartlett's test²⁹ is one of the earliest methods used to test the inequality of variance but known to be sensitive to the violation of normality assumption²⁸. The Bartlett's test-statistic is

$$\frac{(n-k)ln(S_p^2) - \sum_{i=1}^k (n_i - 1)ln(S_i^2)}{1 + \frac{1}{3(k-1)}(\sum_{i=1}^k (\frac{1}{n_i - 1}) - \frac{1}{n-k})} \sim \chi_{k-1}^2$$

where *n* is the total sample size; *k* is the number of groups; n_i is the sample size of the *i*-th group, $n = \sum_{i=1}^{k} n_i$; S_i^2 is the sample variance in the *i*-th group; S_p^2 is the pooled estimate of the variance, $S_p^2 = \frac{1}{n-k} \sum_{i=1}^{k} (n_i - 1) S_i^2$. We used the *bartlett.test()* function in R for data analysis.

The Fligner-Killeen (median) test³² is a rank-based method with similar performance to the Levene's test. The Fligner-Killeen test-statistic is

$$\frac{\sum_{i=1}^{k} n_i \, (\overline{A}_i - \overline{a})^2}{V^2} \sim \chi_{k-1}^2$$

where *n* is the total sample size; *k* is the number of groups; n_i is the sample size of the *i*-th group, $n = \sum_{i=1}^k n_i$; *a* is the "rank score" assigned by $\Phi^{-1}(\frac{1+\frac{j}{n+1}}{2})$ with *j* being the rank of all observations based on $|y_{ij} - \tilde{y_i}|$, $\tilde{y_i}$ being the median of the *i*-th group and Φ^{-1} being the standard normal quantile function; $\overline{A_i}$ is the mean rank score of the *i*-th group; \overline{a} is the mean rank score of all observations; V^2 is the sample variance of rank scores of all observations. We used the *fligner.test()* function in R for data analysis.

Ronnegard et al.^{33,34} proposed a double generalized linear model (DGLM)³⁵ that contained two linear models, one for the effect on the trait mean and the other for the effect on the trait variance

$$E(y|u, u_d) = \mu; \ \mu = Xb + Zu$$

$$var(y|u, u_d) = \phi; \ log(\phi) = X_d b_d + Z_d u_d$$

where y is the phenotype; u and u_d are the random effects on the mean and variance (dispersion), respectively; b and b_d are the fixed effects on the mean and variance (dispersion), respectively. We used "dglm" package in R for data analysis.

Note S3. Rank-based inverse-normal transformation

We used the simulated data to compare several phenotype processing strategies. Rank-based inverse-normal transformation (RINT) was conducted based on the formula below^{68,69}

$$y_i^t = \Phi^{-1}\left(\frac{r_i-c}{n-2c+1}\right)$$

where r_i is the ordinary rank of the *i*-th observation; *n* is the total number of observations; *c* is a constant value (set to 0.5 in this study); Φ^{-1} is the standard normal quantile function; y_i^t is the transformed value for the *i*-th observation. For RINT after covariate adjustment, we first adjusted the phenotypes for covariates and then transformed the residuals by RINT.

Note S4. The effective number of independent traits

As some phenotypes were correlated with each other (Figure S2a), we used an eigendecomposition analysis to estimate the effective number of independent traits⁶⁶. Let **y** be a vector of *p* phenotypes and **V** be the variance-covariance matrix of vector **y**. The eigen decomposition of matrix **V** is

$V = Q' \Lambda Q$

where **Q** is the matrix of eigenvectors and **A** is the diagonal matrix comprised of the ordered eigenvalues $\lambda_1 \dots \lambda_p$. The effective number of *p* phenotypes can be estimated as⁶⁶

$$\frac{(\sum_{k=1}^p \lambda_k)^2}{\sum_{k=1}^p \lambda_k^2}$$

Note S5. Definitions of the three environmental factors—PA, SB, and smoking

Physical activity (PA) was assessed based on the questions from International Physical Activity Questionnaire (IPAQ)⁷⁰, including the number of days per week of walking (DayW), the number of days per week of moderate physical activity (DayW), the number of days per week of vigorous physical activity more than 10 minutes (DayV), the duration of walking (DurW), the duration of moderate physical activity (DurM), and the duration of vigorous physical activity (DurV) (Table S1b). According to the IPAQ analysis guideline⁶⁷, the metabolic equivalents (MET) minutes for walking (METW), moderate physical activity (METM), vigorous physical activity (METV), and the total MET (METT) minutes were calculated by

METW = $3.3 \times DayW \times DurW$ METM = $4.0 \times DayM \times DurM$ METV = $8.0 \times DayV \times DurV$

METT = METW + METM + METV

The physical activity level was then labelled as 1) "high" (coded as 3) when "DayV≥3 and METT≥1500" or "DayW+DayM+DayV≥7 and METT≥3000"; 2) "moderate" (coded as 2) when "DayV≥3 and DurV≥20" or "DayM≥5 and DurM≥30" or "DayW≥5 and DurW≥30" or "DayW+DayM+DayV≥5 and METT≥600"; 3) "low" (coded as 1) when no activity or some activity was reported but not enough to meet the criteria above.

Sedentary behaviour (SB) was defined as the sum of the time spent driving (TimeD), non-work-related computer using (TimeC) or TV watching (TimeTV) (Table S1b). We removed outliers 5 SD from the mean; the remaining data ranged from 0 to 17 hours.

Smoking was assessed based on the answers to two questions about current tobacco smoking (CurS) and past tobacco smoking (PastS) (Table S1b). Individuals were classified as "never smoker" (coded as 0) if CurS = "no" and PastS = "tried once or twice" or "never". Individuals were classified as "ever smoker" (coded as 1) if CurS = "most days" or "occasionally", or PastS = "most days" or "occasionally".

Note S6. Expected inflation in the Levene's test statistic due to phantom vQTL effect

6.1 Two loci

Let us consider two genetic loci A and B, and let p_A and p_B denote the frequencies of the major alleles of A and B, respectively, and p_{AB} denote the haplotype frequency of the two major alleles. We know that the LD (including D, D' and r^2) between the two loci, the genotype frequencies of the two loci, and the genotype frequency of locus A conditional on locus B are a function of p_A , p_B and p_{AB}^{71} .

Allele and haplotype frequencies

	Locus B				
Locus A	Major allele B	Minor allele b	Allele frequency		
Major allele A	p_{AB}	$p_{Ab} = p_A - p_{AB}$	p_A		
Minor allele a	$p_{aB} = p_B - p_{AB}$	$p_{ab} = 1 - p_A - p_B + p_{AB}$	$p_a = 1 - p_A$		
Allele frequency	p_B	$p_b = 1 - p_B$	1		

 p_{AB} and LD between A and B as a function of p_A and p_B

Measures	Definition	Maximum value	Minimum value
p_{AB}	-	$min[p_A, p_B]$	$p_A + p_B - 1$
D	$D = p_{AB} - p_A \times p_B$	$min[p_A(1-p_B), p_B(1-p_A)]$	$-(1-p_A)(1-p_B)$
	$D' = \frac{D}{\min[p_A(1-p_B), p_B(1-p_A)]}$, if D		
D'	> 0 $D' = \frac{D}{min[p_A p_B, (1 - p_A)(1 - p_B)]}, \text{ if } D$ < 0	1	-1
r^2	$r^2 = \frac{D^2}{p_A p_B (1 - p_A)(1 - p_B)}$	$min[rac{p_A(1-p_B)}{(1-p_A)p_B},rac{(1-p_A)p_B}{p_A(1-p_B)}]$	0

Genotype	freq	mencies	of	the	two	loci
uchotype	nuq	Jucheres	01	une	100	1001

	Genotype BB	Genotype Bb	Genotype bb	Genotype Frequency
Genotype AA	$p_{AABB} = p_{AB}^2$	$p_{AABb} = 2p_{AB}p_{Ab}$ $= 2p_{AB}(p_A - p_{AB})$	$p_{AAbb} = p_{Ab}^2 = (p_A - p_{AB})^2$	p_A^2

Genotype Aa	$p_{AaBB} = 2p_{AB}p_{aB}$ $= 2p_{AB}(p_B - p_{AB})$	$p_{AaBb} = 2(p_{AB}p_{ab} + p_{Ab}p_{aB})$ = 2[p_{AB}(1 - p_A - p_B + p_{AB}) +(p_A - p_{AB})(p_B - p_{AB})]	$p_{Aabb} = 2p_{Ab}p_{ab}$ $= 2(p_A - p_{AB})(1 - p_A - p_B)$ $+ p_{AB})$	$2p_A(1-p_A)$
Genotype aa	$p_{aaBB} = p_{aB}^2$ $= (p_B - p_{AB})^2$	$p_{aaBb} = 2p_{aB}p_{ab}$ $= 2(p_B - p_{AB})(1 - p_A - p_B + p_{AB})$	$p_{aabb} = p_{ab}^2$ $= (1 - p_A - p_B + p_{AB})^2$	$(1-p_A)^2$
Genotype Frequency	p_B^2	$2p_B(1-p_B)$	$(1-p_B)^2$	1

Genotype frequency of locus A conditioning on locus B

Genotype	AA	Aa	aa
	$P(AA \mid BB) = \frac{p_{AABB}}{p_{BB}}$	$P(Aa \mid BB) = \frac{p_{AaBB}}{p_{BB}}$	$P(aa \mid BB) = \frac{p_{aaBB}}{p_{BB}}$
ВВ	$=rac{p_{AB}^2}{p_B^2}$	$=\frac{2p_{AB}(p_B-p_{AB})}{p_B^2}$	$=rac{(p_B-p_{AB})^2}{p_B^2}$
DL	$P(AA \mid Bb) = \frac{p_{AABb}}{p_{Bb}}$	$P(Aa \mid Bb) = \frac{p_{AaBb}}{p_{Bb}}$	$P(aa \mid Bb) = \frac{p_{aaBb}}{p_{Bb}}$
BD	$=\frac{p_{AB}(p_A-p_{AB})}{p_B(1-p_B)}$	$=\frac{p_{AB}(1-p_A-p_B+p_{AB})+(p_A-p_{AB})(p_B-p_{AB})}{p_B(1-p_B)}$	$=\frac{(p_B - p_{AB})(1 - p_A - p_B + p_{AB})}{p_B(1 - p_B)}$
b b	$P(AA \mid bb) = \frac{p_{AAbb}}{p_{bb}}$	$P(Aa \mid bb) = \frac{p_{Aabb}}{p_{bb}}$	$P(aa \mid bb) = \frac{p_{aabb}}{p_{bb}}$
UU	$=\frac{(p_A - p_{AB})^2}{(1 - p_B)^2}$	$=\frac{2(p_A - p_{AB})(1 - p_A - p_B + p_{AB})}{(1 - p_B)^2}$	$=\frac{(1-p_A-p_B+p_{AB})^2}{(1-p_B)^2}$

6.2 Causal variant (locus A) with an additive genetic effect

Let us assume that locus A is the causal variant with an additive genetic effect (b_c) on a phenotype

$$y \sim (\mu + b_c x_a, \sigma^2)$$

Genotype	Code (x_a)	$E(y x_a)$	$Var(y x_a)$	$E(y^2 x_a)$
AA	0	μ	σ^2	$\sigma^2 + \mu^2$
Aa	1	$\mu + b_c$	σ^2	$\sigma^2 + (\mu + b_c)^2$
aa	2	$\mu + 2b_c$	σ^2	$\sigma^2 + (\mu + 2b_c)^2$

Genotype	Code (x_b)	$E(y x_b)$		
BB	0	$\mu + \frac{2b_c(p_B - p_{AB})}{p_B}$		
Bb	1	$\mu + \frac{b_c(2p_B - p_{AB} - 2p_B^2 + 2p_Bp_{AB} - p_Ap_B)}{p_B(1 - p_B)}$		
		$= \mu + \frac{b_c[(p_B - p_{AB})(1 - p_B) + (1 - p_A - p_B + p_{AB})p_B]}{p_B(1 - p_B)}$		
bb	2	$\mu + \frac{2b_c(1 - p_A - p_B + p_{AB})}{1 - p_B}$		
		$Var(y x_b)$		
$\sigma^2 + \frac{2{b_c}^2(p_E)}{2}$	$\frac{p_B^2-p_{AB})p_{AB}}{p_B^2}$			
σ^2				
$+\frac{b_c^{\ 2}(p_Bp_{AB}-p_{AB}^2+2p_Bp_{AB}^2-3p_B^2p_{AB}+p_Ap_B^2-2p_B^2p_{AB}^2+2p_Ap_B^2p_{AB}+2p_B^3p_{AB}-p_Ap_B^3-p_A^2p_B^2)}{p_B^2(1-p_B)^2}$				
$= \sigma^2 + b_c^2[($	$(p_B - p_{AB})p_A$	$\frac{p_B(1-p_B)^2 + (1-p_A - p_B + p_{AB})(p_A - p_{AB})p_B^2]}{p_B^2(1-p_B)^2}$		
$\sigma^2 + \frac{2{b_c}^2(1)}{2}$	$\frac{-p_A - p_B + p_B}{(1 - p_B)}$	$\frac{p_{AB})(p_A - p_{AB})}{(p_B)^2}$		

The expected phenotypic mean and variance given a genotype of locus B (marker) can be found in the tables below.

We therefore can observe an additive effect on both mean (b_m) and variance (β_m) at the marker (locus B)

$$y \sim (\mu_m + b_m x_b, \sigma^2_m + \beta_m x_b)$$

where

-
$$\mu_m = \mu + \frac{2b_c(p_B - p_{AB})}{p_B}$$

- $b_m = \frac{b_c(p_{AB} - p_A p_B)}{p_B(1 - P_B)}$

$$- \sigma_m^2 = \sigma^2 + \frac{2b_c^2(p_B - p_{AB})p_{AB}}{p_B^2}$$
$$- \beta_m = \frac{b_c^2[(1 - 2p_B)p_{AB}^2 + (2p_A p_B + p_B - 1)p_B p_{AB} + (1 - p_A - p_B)p_A p_B^2]}{p_B^2(1 - p_B)^2}$$

6.3 QTL test-statistics at the marker variant (locus B)

Assuming phenotypic variance of 1 (i.e., var(y) = 1), the variance explained by the marker variant (q_m^2) and the non-centrality parameter (NCP) of a chi-squared test for QTL effect at the marker can be written as

$$- q_m^2 = 2p_B(1-p_B)b_m^2 = 2p_B(1-p_B)\frac{b_c^2(p_{AB}-p_Ap_B)^2}{p_B^2(1-p_B)^2} = \\ - 2p_A(1-p_A)b_c^2\frac{(p_{AB}-p_Ap_B)^2}{p_A(1-p_A)p_B(1-p_B)} = q_c^2r^2$$

- NCP =
$$\frac{nq_m^2}{1-q_m^2} = \frac{nq_c^2r^2}{1-q_c^2r^2}$$

where *n* is the sample size, q_c^2 is the variance explained by the causal variant, and r^2 is the LD between the causal and the marker variants. This derivation is consistent with that in previous studies^{72,73}.

6.4 vQTL test statistic at the marker variant (locus B)

Under normality assumption, the distribution of the phenotype with respect to the marker variant can be written as

$$y \sim N(\mu_m + b_m x_b, \sigma^2_m + \beta_m x_b)$$

We then have

$$y - E(y|x_b) \sim N(0, \sigma^2_m + \beta_m x_b)$$

and $z = |y - \tilde{y}|$

$$z = |y - \tilde{y}| = |y - E(y|x_b)|$$

~ Folded Normal Distribution($\sqrt{\frac{2}{\pi}(\sigma_m^2 + \beta_m x_b)}, (1 - \frac{2}{\pi})(\sigma_m^2 + \beta_m x_b))$

Genotype	Code (x_b)	$\mathrm{E}(z x_b)$	$var(z x_b)$	$E(z^2 x_b)$
BB	0	$\sqrt{\frac{2}{\pi}\sigma^2_m}$	$(1-\frac{2}{\pi})\sigma^2_m$	σ^2_m
Bb	1	$\sqrt{\frac{2}{\pi}(\sigma^2_m + \beta_m)}$	$(1-\frac{2}{\pi})(\sigma^2_m+\beta_m)$	$\sigma^2_m + \beta_m$
bb	2	$\sqrt{\frac{2}{\pi}(\sigma^2_m + 2\beta_m)}$	$(1-\frac{2}{\pi})(\sigma^2_m+2\beta_m)$	$\sigma^2_m + 2\beta_m$

$$E(z) = E(z|x_b = 0)P(x_b = 0) + E(z|x_b = 1)P(x_b = 1) + E(z|x_b = 2)P(x_b = 2)$$

$$= \sqrt{\frac{2}{\pi}\sigma_{m}^{2}p_{B}^{2}} + \sqrt{\frac{2}{\pi}(\sigma_{m}^{2} + \beta_{m})^{2}p_{B}(1 - p_{B})} + \sqrt{\frac{2}{\pi}(\sigma_{m}^{2} + 2\beta_{m})(1 - p_{B})^{2}}$$

$$E(z^{2}) = E(z^{2}|x_{b} = 0)P(x_{b} = 0) + E(z^{2}|x_{b} = 1)P(x_{b} = 1) + E(z^{2}|x_{b} = 2)P(x_{b} = 2)$$

$$= \sigma_{m}^{2} p_{B}^{2} + (\sigma_{m}^{2} + \beta_{m})^{2} p_{B}(1 - p_{B}) + (\sigma_{m}^{2} + 2\beta_{m})(1 - p_{B})^{2}$$

$$= \sigma^2_m + 2(1 - p_B)\beta_m$$

$$var(z) = E(z^{2}) - [E(z)]^{2} = \sigma_{m}^{2} + 2(1 - p_{B})\beta_{m} - [E(z)]^{2}$$

The Levene's test is essentially one-way ANOVA test on the variable *z* (see the Methods section). We therefore have

$$E(SST) = E[\sum_{i=1}^{k} \sum_{j=1}^{n_i} (z_{ij} - z_{..})^2] = Var(z)n = (\sigma_m^2 + 2(1 - p_B)\beta_m - [E(z)]^2)n;$$

$$E(SSE) = E\left[\sum_{i=1}^{k}\sum_{j=1}^{n_{i}}(z_{ij}-z_{i.})^{2}\right]$$

$$= (1-\frac{2}{\pi})\sigma^{2}_{m}np_{B}^{2} + (1-\frac{2}{\pi})(\sigma^{2}_{m}+\beta_{m})n2p_{B}(1-p_{B}) + (1-\frac{2}{\pi})(\sigma^{2}_{m}+2\beta_{m})(1-p_{B})^{2}$$

$$= (1-\frac{2}{\pi})(\sigma^{2}_{m}+2(1-p_{B})\beta_{m})n;$$

$$E(SSR) = E(SST-SSE) = \left[\frac{2}{\pi}(\sigma^{2}_{m}+2(1-p_{B})\beta_{m}) - [E(z)]^{2}\right]n;$$

$$F_{\text{Levene}} = \frac{(n-3)E(SSR)}{(3-1)E(SSE)} \approx \frac{n}{2}\frac{E(SSR)}{E(SSE)} = \frac{n\frac{2}{\pi}(\sigma^{2}_{m}+2(1-p_{B})\beta_{m}) - [E(z)]^{2}}{(1-\frac{2}{\pi})(\sigma^{2}_{m}+2(1-p_{B})\beta_{m})}$$

$$=\frac{n}{\pi-2}\left(1-\frac{\left[\sqrt{\sigma_{m}^{2}}p_{B}^{2}+\sqrt{\sigma_{m}^{2}}+\beta_{m}^{2}}2p_{B}(1-p_{B})+\sqrt{\sigma_{m}^{2}}+2\beta_{m}^{2}(1-p_{B})^{2}\right]^{2}}{\sigma_{m}^{2}+2(1-p_{B})\beta_{m}}\right)$$

where F_{Levene} is the Levene's *F*-statistic; *SST*, *SSR* and *SSR* are the total sum of squares, regression sum of squares and error sum of squares, respectively, as defined in an ANOVA analysis.

Given that var(y) = 1, we can replace b_c^2 with $\frac{q_c^2}{2p_A(1-p_A)}$, and σ^2 with $1 - q_c^2$

$$\beta_m = \frac{q_c^2[(1-2p_B)p_{AB}^2 + (2p_Ap_B + p_B - 1)p_Bp_{AB} + (1-p_A - p_B)p_Ap_B^2]}{2p_A(1-p_A)p_B^2(1-p_B)^2}$$

$$\sigma_m^2 = 1 - q_c^2 + \frac{(p_B - p_{AB})p_{AB}}{p_A(1 - p_A)p_B^2}q_c^2$$

 F_{Levene}

$$=\frac{n}{\pi-2}\left(1-\frac{[\sqrt{\sigma_m^2}p_B^2+\sqrt{\sigma_m^2+\beta_m^2}2p_B(1-p_B)+\sqrt{\sigma_m^2+2\beta_m^2}(1-p_B)^2]^2}{\sigma_m^2+2(1-p_B)\beta_m}\right)$$

Therefore, the phantom vQTL test statistic is a function of sample size *n*, variance explained by the causal variant q_c^2 , allele frequency of the causal variant p_A , allele frequency of the marker variant p_B , and the haplotype frequency p_{AB} . This formula has been confirmed by simulation (Figure S7a). We then computed F_{Levene} given a number of parameters including p_{AB} (equivalent to D' ranging from -1 to 1), p_a (ranging from 0.001 to 0.5, equivalent to p_A from 0.999 to 0.5), p_b (ranging from 0.05 to 0.5, equivalent to p_B from 0.95 to 0.5), q_c^2 (= 0.005, 0.01 or 0.02) and n (= 350,000) (Figure S7b-d).

Note S7. Acknowledgments

This study has been conducted using the UK Biobank resource under Application Number 12505. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government, British Heart Foundation and Diabetes UK.

Supplementary Figures



Fig. S1. Evaluation of statistical methods and phenotype processing strategies for the vQTL analysis by simulation based on a single-SNP model. Evaluation of statistical methods

(a) and phenotype processing strategies (b) for vQTL analysis by simulation based on a single-SNP model. Phenotypes of 10,000 individuals were simulated based on one SNP and one error term in a single-SNP model (Methods). The SNPs effects were simulated under four scenarios: 1) effect on neither mean nor variance (nei), 2) effect on mean only (mean), 3) effect on variance only (var), or 4) effect on both mean and variance (both). The error term was generated from 5 different distributions: normal distribution, *t*-distribution with degree of freedom (df) = 10 or 3, or χ^2 distribution with df = 15 or 1. Four statistical test methods, i.e. the Bartlett's test (Bart), the Levene's test (Lev), the Fligner-Killen test (FK) and the DGLM, were used to detect vQTLs. In panel b, the Levene's test was used to analyse phenotypes processed using five strategies, i.e. raw phenotype (raw), raw phenotype adjusted for covariates (adj), rank-based inverse-normal transformation after adj (rint), logarithm transformation after adj (log), square transformation after adj (sq), and cube transformation after adj (cub). Positive rate is defined as the number of vQTLs with p < 0.05 divided by the total number of tests across 1,000 simulations, which is the FPR under the null ("nei" and "mean") and power under the alternative ("var" and "both"). The red horizontal line represents an FPR of 0.05.



Fig. S2. Phenotypic correlations among 13 quantitative traits, and PA and SB measures in the UKB. Phenotypic correlations among (a) 13 quantitative traits and (b) PA and SB measures in the UKB. The Pearson's correlation coefficient was calculated between each pair of (a) the processed phenotypes or (b) the PA and SB measures. The order shown on the plot above was determined by hierarchical cluster analysis using the R function *hclust()*.



Fig. S3. Genome-wide vQTL and QTL analyses for 13 traits in the UKB. (a) Spurious vQTL association due to the coincidence of a minor allele with a phenotypic outlier. This is an example that a spurious vQTL signal ($P_{vQTL} = 4.48 \times 10^{-9}$) at a low-MAF variant (MAF = 0.012) is caused by the coincidence of a minor allele with a phenotypic outlier for FVC. The variance of the phenotype (after covariates adjustment and standardisation) are 1.00, 0.83 and **20.20** in the three genotype groups of rs11102024 respectively. Note that for all the other vQTL results

presented in this paper are from analyses excluding individuals with adjusted phenotypes more than 5 SD from the mean and SNPs with MAF < 0.05. (b) vQTL regional plot at the *FTO* locus for 5 traits. For each of the 5 traits for which the phenotypic variance is significantly associated with the *FTO* locus, vQTL test statistics $(-\log_{10}(P_{vOTL}))$ are plotted against SNP positions surrounding the top vQTL SNP (represented by a purple diamond) at the FTO locus. SNPs in different levels of LD with the top vQTL SNP are shown in different colours. The RefSeq genes in the top panel are extracted from the UCSC Genome Browser (URLs). (c) Colocalization and HEIDI tests for the vQTL associations at the FTO locus for the 5 traits. We used the COLOC⁷⁴ method implemented in *R* and the HEIDI method⁷⁵ implemented in SMR (URLs) to test whether the vQTL associations at the FTO locus for the 5 traits as shown in panel (b) are due to the same underlying causal variant. The COLOC and HEIDI analyses were performed for each pair of traits. Note that we convert vQTL p-values to vQTL effect sizes and standard errors using the method described in Zhu et al.⁷⁵ (with the direction of each vQTL effect determined by comparing the phenotypic variance among the genotype classes of a SNP) for the HEID analysis. The COLOC PP4 values (up-right off-diagonal), the posterior possibility for hypothesis 4 (i.e., association signals at a locus for two traits are driven by a shared causal variant), were all greater than 80%, and the HEIDI p-values (down-left off-diagonal), testing against the null hypothesis that the association signals for two traits at a locus are driven by the same set of causal variants, were all larger than 0.05. (d) A plot of test statistic $(-\log_{10}(P_{vQTL}))$ against MAF for the 41 independent vQTLs across traits. (e-f) Manhattan plots of genome-wide vQTL analysis for height squared (e) and cubed (f) in the UKB. Test statistics ($-\log_{10}(P_{vQTL})$) of all common (MAF ≥ 0.05) SNPs from the vQTL analysis are plotted against their physical positions. The blue horizontal line represents the genome-wide significance level 1.0×10^{-8} and the red horizontal line represents the experiment-wise significance level 2.0×10^{-9} . (g) QTL and vQTL regional plots at the *CCDC92* or *FTO* locus for waist circumference. The QTL and vQTL test statistics (i.e., $-\log_{10}(P \text{ values}))$ for waist circumference are plotted against SNP positions surrounding the top vQTL SNP at the *CCDC92* (panel a) or *FTO* locus (panel b). The top vQTL SNP is represented by a purple diamond. SNPs in different levels of LD with the top vQTL SNP are shown in different colours. The RefSeq genes in the top panel are extracted from the UCSC Genome Browser (URLs).





FEV



Expected -log₁₀(P)

BMI



5

6

Ż

FVC

œ





Fig. S4. Quantile-quantile plots of vQTL associations for the 13 UKB traits. For each trait, we shown the QQ plots for all SNPs including (red) or excluding (blue) the top vQTLs and SNPs in LD with them (determined by GCTA-LDF⁶⁵). The area highlighted in grey is the 95% confidence interval.



Fig. S5. Enrichment of GEI effects among the 75 vQTLs compared with a random set of QTLs using the raw phenotypic values. Five environmental factors, i.e., sex, age, physical activity (PA), sedentary behaviour (SB), and smoking, were used in the GEI analysis. (a) The heatmap plot of GEI test statistics ($-\log_{10}(P_{GEI})$) for the 75 top vQTL SNPs. "*" denotes significant GEI effects after Bonferroni correction ($P_{GEI} < 1.33 \times 10^{-4} = 0.05/75/5$). (b) The distribution of the number of significant GEI effects for 75 top QTL SNPs randomly selected from all the top QTL SNPs with 1000 repeats (mean 3.56 and SD 1.76). The red line represents the number of significant GEI effects for the 75 top vQTL SNPs (i.e., 21).



Fig. S6. Comparison of the Young *et al.* **method with the Levene's test by vQTL simulation.** While we were preparing the manuscript, a very recent study from Young et al.⁴⁰ developed an efficient algorithm for fitting DGLM (called heteroskedastic linear mixed model or HLMM) and proposed a dispersion effect test (DET) to remove the impact of the QTL effects on the vQTL signals. We used our multiple-SNP simulation setting (Figure 2 and Methods) to quantify the FPR and power of the Young et al. method (HLMM + DET) in comparison with the Levene's test based on the phenotype after 1) covariate adjustment ("adj") or 2) covariate adjustment followed by rank-based inverse-normal transformation ("rint"). For the Levene's test, the positive rate (FPR or power) was computed as the number of vQTLs with p < 0.05 divided by the total number of tests across simulations.



Fig. S7. Excluding two alternative explanations for vQTL signals: Phantom vQTLs and epistasis. (a) Verification of the expected Levene's test *F*-statistic due to phantom vQTL effect by simulation. We simulated two variants A ($p_A = 0.7$) and B ($P_B = 0.6$) in LD ($P_{AB} = 0.6$, LD $r^2 =$ 0.64, and LD D' = 1) from multinomial(2, (P_{AB}, P_{Ab}, PaB, Pab)) and a phenotype based on the causal variant A explaining 5% variance in 350,000 individuals. Shown is the distribution of *F*statistics from the Levene's test using the simulated data with 1,000 replicates. The red line indicates the theoretical value based on the formula in Note S6.4. (b-d) Expected phantom vQTL *F*-statistics from the Levene's test. We calculated the expected phantom vQTL *F*-statistics given a number of parameters including p_{AB} (equivalent to LD D' from -1 to 1), p_a (ranging from 0.001 to 0.5), p_b (ranging from 0.05 to 0.5), q_c^2 (= 0.005, 0.01 or 0.02) and n (= 350,000) (Note S6 for more details). An *F* value of 18.4 is equivalent to a genome-wide significant p-value of 1×10⁻⁸. (e) Estimated variance explained by top QTL SNPs for the 13 UKB traits. Note that because the phantom vQTL signals at common SNPs can be induced by rare (MAF<0.01) or low-frequency (0.01≤MAF<0.05) variants, we extended our GWAS analysis to all 44,741,800 imputed variants (MAF<0.05). The estimated variance explained by each GWAS top SNP is plotted against its MAF. (f) vQTL test statistics ($-log_{10}(P_{vQTL})$) from analyses with and without adjusting the phenotype for the QTL effect(s) of the top GWAS SNP(s) within 10Mb of the top vQTL SNP. The red line represents the line with slope 1 and intercept 0. (g) Manhattan plot of epistasis analysis for one of top vQTL SNPs. We conducted epistasis analysis between each of 75 top vQTL SNPs and any other SNPs in more than 10 Mb distance or on a different chromosome for the relevant trait using PLINK2⁶³ (--epistasis option). The blue horizontal line represents the genome-wide significance level (i.e., p-value = 1×10⁻⁸). Shown are the results from the epistasis analysis with the top vQTL SNP rs10913469 for waist circumference (WC).

Supplementary Tables

Table S1. Descriptive summary of (A) the quantitative traits and (B) the environmental data used in this study from the UKB.

Trait	Description	Sample size	UDIa
HT	Standing height	347,086	50-0.0
FVC	Forced vital capacity	317,222	3062-0.0
FEV1	Forced expiratory volume in 1-second	317,285	3063-0.0
FFR ^b	FEV1 and FVC ratio	316,614	NA
PMD	Heel bone mineral density T-score,	107 261	79.00
	automated	197,201	78-0.0
BW	Birth weight	197,758	20022-0.0
BMI	Body mass index (BMI)	346,393	21001-0.0
WC	Waist circumference	347,158	48-0.0
НС	Hip circumference	346,781	49-0.0
WHRc	Waist to Hip Ratio	347,134	NA
WHRadjBMI ^d	WHR adjusted for BMI	346,535	NA
BFP	Body fat percentage	341,632	23099-0.0
BMR	Basal metabolic rate	341,584	23105-0.0

(a) 13 quantitative traits

(b) Environmental data used in the GEI analysis.

Item	Description	UDI ^a
Sex	Sex	31-0.0
Age	Year of birth	34-0.0
DayW	Number of days/week walked 10+ minutes	864-0.0
DurW	Duration of walks	874-0.0
DayM	Number of days/week of moderate physical activity 10+	004 0 0
	minutes	004-0.0
DurM	Duration of moderate activity	894-0.0
DavV	Number of days/week of vigorous physical activity 10+	904 0 0
Dayv	minutes	904-0.0
DurV	Duration of vigorous activity	914-0.0
TimeD	Time spent driving	1090-0.0
TimeC	Time spent using computer	1080-0.0
TimeTV	Time spent watching television (TV)	1070-0.0

CurS	Current tobacco smoking	1239-0.0
PastS	Past tobacco smoking	1249-0.0

Note: a) UDI, the Unique Data Identifier in the UKB dataset; b) FFR is the ratio of FEV1 to FVC; c) WHR is the ratio of waist circumference to hip circumference; d) WHRadjBMI is the residual after adjusting WHR for BMI.

Tr ait	C H R	SNP	bp	Neares t Gene	MA F	vQTL p- value	QTL p- value	Phenotypic variance in each genotype group	Phenotypic mean in each genotype group
FF R	4	rs65372 92	14546 9968	HHIP	0.3 94	1.97E -14	3.58E- 122ª	1.0217,0.993 6,0.9561	- 0.0453,0.0091, 0.0787
	5	rs12374 521	14783 6880	FBXO3 8	0.4 56	7.10E -10	1.60E- 58	1.0223,0.997 8,0.97	- 0.039,0.0055,0 .0417
	15	rs56077 333	78899 003	CHRN A3	0.3 25	1.09E -14	2.11E- 06	0.9757,1.010 7,1.0588	0.0072,- 0.0019,- 0.0225
BM D	1	rs14146 60	24058 6695	GREM 2	0.1 92	7.83E -14	1.28E- 94	0.977,1.0362, 1.0452	- 0.0322,0.0523, 0.1304
	6	rs93712 21	15188 5986	CCDC1 70	0.1 01	4.59E -10	1.30E- 76	1.0097,0.950 2,0.9408	0.02,-0.0817,- 0.1479
	6	rs30203 32	15200 8924	ESR1	0.4 5	5.42E -14	8.94E- 130	0.966,0.997,1 .0429	- 0.074,0.0126,0 .0795
	7	rs45763 34	38153 747	STARD 3NL	0.1 96	2.36E -13	2.60E- 86	0.9784,1.030 8,1.0684	- 0.0325,0.0511, 0.1152
	7	rs10254 825	12095 6440	WNT1 6	0.3 91	2.01E -45	0	0.9279,1.010 7,1.057	- 0.1455,0.05,0. 1903
	11	rs60314 0	86884 615	TMEM 135	0.3 12	1.61E -12	4.48E- 98	1.0149,0.992 4,0.9333	0.0417,- 0.0204,- 0.1142
B W	3	rs13322 435	15679 5468	CCNL1	0.4 02	9.71E -10	6.21E- 48	1.0287,0.984 7,0.9742	0.0376,- 0.0072,-

Table S2. Seventy-five experiment-wise significant vQTLs for nine UKB traits.(a) The vQTL and QTL tests.

								0.0585
BM I	rs54560 8	17789 9121	SEC16 B	0.2 06	3.88E -17	1.97E- 63	0.9801,1.025 1,1.0835	- 0.0202,0.0282, 0.0847
1	rs66893 35	21962 8682	LYPLA L1	0.4 19	2.86E -12	4.73E- 08	1.0249,0.990 7,0.972	0.0106,- 0.0013,- 0.0167
2	rs62104 180	46600 3	FAM1 50B	0.0 5	1.22E -11	3.57E- 51	1.0054,0.946 1,0.8598	0.0083,- 0.075,-0.1488
2	rs67519 93	63586 4	TMEM 18	0.1 67	3.50E -18	3.31E- 65	1.0155,0.970 7,0.9188	0.0197,- 0.0361,- 0.0912
2	rs10203 386	25136 866	ADCY3	0.4 52	1.33E -11	8.45E- 43	0.9768,0.999 4,1.0333	-0.0272,3e- 04,0.0404
2	rs16411 55	58965 211	FANCL	0.3 11	1.25E -09	4.42E- 17	0.9872,1.009 2,1.0266	- 0.0141,0.0108, 0.0266
3	rs12250 53	13164 2852	CPNE4	0.2 64	1.69E -12	2.85E- 17	0.9863,1.009, 1.0577	- 0.0109,0.0073, 0.0444
4	rs10016 841	20213 781	SLIT2	0.1 33	1.95E -09	2.11E- 13	0.9898,1.027 2,1.0621	- 0.007,0.0187,0 .0468
4	rs12507 026	45181 334	GNPD A2	0.4 34	1.84E -11	6.78E- 41	0.9762,0.999 8,1.0381	-0.0243,-6e- 04,0.0435
6	rs34817 112	27176 628	PRSS1 6	0.1 34	8.48E -17	3.51E- 08	0.9857,1.041 6,1.0635	- 0.0054,0.0154, 0.026
6	rs31329 47	32176 782	GPSM3	0.2 18	2.36E -13	8.53E- 15	0.9834,1.021 4,1.0563	- 0.0096,0.0119, 0.038
6	rs98723 7	50803 050	TFAP2 B	0.1 8	2.18E -16	7.51E- 43	0.9842,1.024 9,1.0845	- 0.0148,0.0247, 0.0833
8	rs17150 703	97457 98	MSRA	0.1 04	1.38E -09	2.05E- 11	0.9925,1.024	- 0.0053.0.0196

	10 11 12	rs41326 70 rs20490 45 rs71329 08	11476 7771 27694 241 50263 148	TCF7L 2 BDNF BCDIN 3D	0.3 12 0.1 87 0.3 85	3.88E -11 6.91E -10 3.73E -11	2.75E- 15 8.20E- 42 3.94E- 32	1.0205,0.986, 0.9606 1.0115,0.979 4,0.9461 0.9791,1.002 4,1.0429	0.0583 0.0133,- 0.0084,- 0.0263 0.0162,- 0.0288,- 0.0563 - 0.0563 - 0.0211,0.0046, 0.0392
	12	rs11057 413	12448 9162	ZNF66 4- FAM1 01A	0.3 34	1.05E -10	6.30E- 09	0.981,1.0071, 1.0456	- 0.0104,0.0064, 0.0173
	16	rs40724 02	28937 259	RABEP 2	0.3 37	5.55E -12	2.72E- 28	0.9802,1.007 6,1.0463	- 0.0185,0.0081, 0.0393
	16	rs12716 979	31011 821	STX1B	0.3 75	1.40E -16	7.30E- 24	1.031,0.9897, 0.9517	0.0186,- 0.0053,- 0.0328
	16	rs11642 015	53802 494	FTO	0.4 04	1.73E -73	7.43E- 217	0.9398,1.001 3,1.1095	- 0.0555,0.005,0 .1062
	18	rs10871 777	57851 763	MC4R	0.2 36	1.73E -19	3.01E- 81	0.9767,1.023 2,1.0751	- 0.0248,0.0262, 0.0897
	19	rs22386 91	46179 043	GIPR	0.1 94	3.46E -15	2.31E- 32	1.0176,0.970 6,0.9309	0.0142,- 0.0231,- 0.0537
W C	1	rs10913 469	17791 3519	SEC16 B	0.2 05	3.80E -14	4.50E- 44	0.9848,1.018 9,1.0695	- 0.0166,0.0229, 0.0724
	2	rs62104 180	46600 3	FAM1 50B	0.0 5	3.93E -14	4.02E- 44	1.0061,0.941 7,0.8124	0.0077,- 0.0689,- 0.1472
	2	rs13412	65324	TMEM	0.1	9.76E	1.39E-	1.0134,0.972	0.0176,-

	194	5	18	72	-15	55	6,0.9343	0.0341,- 0.0761
3	rs76499 70	12392 272	PPARG	0.1 21	5.60E -10	5.30E- 10	0.9915,1.024 5,1.0873	- 0.0057,0.0186, 0.0314
4	rs12507 026	45181 334	GNPD A2	0.4 34	2.39E -11	9.40E- 31	0.9757,1.001 6.1.0355	-0.0207,-8e- 04.0.0377
6	rs13198 716	26582 035	ABT1	0.1 09	4.89E -15	0.0305	0.99,1.0363,1 .0714	0.002,0.0078,0 .0046
6	rs10620 70	32148 031	RNF5	0.1 99	7.20E -12	6.06E- 10	0.9862,1.022 1,1.043	- 0.0079,0.0132, 0.0217
6	rs44723 37	34769 765	UHRF1 BP1	0.1 55	5.60E -11	1.78E- 23	0.9893,1.023 7,1.0573	- 0.0105,0.024,0 .0493
6	rs98723 7	50803 050	TFAP2 B	0.1 8	5.43E -12	1.09E- 34	0.9874,1.019 9,1.0669	- 0.0137,0.0239, 0.0663
7	rs12667 251	13044 9458	KLF14	0.4 36	6.82E -12	1.91E- 05	1.025,0.9962, 0.9637	0.0096,- 0.0023,- 0.0109
12	rs71333 78	12440 9502	CCDC9 2	0.3 18	6.25E -10	0.506	0.9845,1.007 1,1.0384	0.001,1e-04,- 0.0034
16	rs80568 90	28897 452	ATP2A 1	0.3 55	5.57E -15	8.85E- 40	0.9759,1.009, 1.0433	- 0.0234,0.0094, 0.0433
16	rs34898 535	31025 641	STX1B	0.3 78	1.11E -11	6.24E- 22	1.0246,0.991, 0.9616	0.0173,- 0.0047,- 0.0316
16	rs14210 85	53800 954	FTO	0.4 04	3.27E -52	3.21E- 166	0.9501,1.004 8,1.0807	- 0.0481,0.0038, 0.0936
18	rs11152 213	57852 948	MC4R	0.2 36	5.62E -15	1.39E- 70	0.9828,1.015 3,1.0646	- 0.0224,0.0224, 0.0898

	19	rs18004 37	46181 392	GIPR	0.1 94	2.05E -11	1.19E- 24	1.0137,0.979 1,0.93	0.0124,- 0.0203,- 0.0445
НС	1	rs66855 93	20351	OPTC	0.4 95	5.99E	2.47E-	0.9682,1.003	-0.016,-3e-
	1	rs26050 98	21964 3649	LYPLA L1	0.3 38	11 1.11E -20	3.87E- 38	0.9723,1.008 5,1.0687	- 0.0209,0.0081, 0.0483
	2	rs62104 180	46600 3	FAM1 50B	0.0 5	1.58E -09	5.56E- 45	1.0054,0.944 7,0.9202	0.0078,-0.07,- 0.1422
	2	rs67519 93	63586 4	TMEM 18	0.1 67	3.84E -12	1.43E- 58	1.0142,0.971 4,0.932	0.0186,- 0.0337,- 0.0883
	2	rs10200 566	25130 462	ADCY3	0.4 51	2.32E -10	2.29E- 18	0.9811,0.997 6,1.0342	- 0.0171,0,0.026
	6	rs34158 769	26336 572	BTN3A 2	0.1 04	5.06E -15	4.20E- 13	0.9881,1.043 6,1.0925	- 0.0061,0.0238, 0.0417
	6	rs31329 47	32176 782	GPSM3	0.2 18	5.34E -11	2.52E- 24	0.9851,1.019, 1.049	- 0.0132,0.0176, 0.0429
	6	rs72891 717	50858 235	TFAP2 B	0.1 69	6.03E -10	1.10E- 36	0.9869,1.022 6,1.0786	- 0.0134,0.0247, 0.0784
	6	rs14178 3576	12743 9897	RSPO3	0.0 67	1.57E -10	4.72E- 32	1.0064,0.948 2,0.994 ^ь	0.0079,- 0.0512,- 0.0833
	7	rs17789 506	13044 5574	KLF14	0.4 93	2.80E -11	1.87E- 18	0.9676,1.000 1,1.0321	-0.0189,- 0.0019,0.0234
	12	rs10846 580	12441 5453	CCDC9 2	0.3 37	7.64E -12	9.27E- 17	0.9793,1.012 2,1.0302	- 0.016,0.0106,0 .0209
	16	rs80568 90	28897 452	ATP2A 1	0.3 55	1.27E -09	1.71E- 41	0.9762,1.010 5,1.0362	- 0.0239,0.0096, 0.0444
	16	rs34898	31025	STX1B	0.3	2.57E	1.58E-	1.0248,0.994	0.0198,-

		535	641		78	-12	27	5,0.9502	0.0054,- 0.0352
	16	rs14210 85	53800 954	FTO	0.4 04	1.65E -48	2.05E- 152	0.9486,1.002 9,1.0909	- 0.0462,0.0039, 0.0893
	18	rs11152 213	57852 948	MC4R	0.2 36	2.39E -16	1.44E- 72	0.98,1.0189,1 .0704	- 0.0237,0.0257, 0.0817
	19	rs22386 91	46179 043	GIPR	0.1 94	4.52E -11	9.80E- 20	1.0162,0.972 7,0.9364	0.0105,- 0.0164,- 0.0467
W HR	5	rs45919 3	55806 751	C5orf6 7	0.2 53	2.86E -13	1.75E- 19	0.9859,1.010 2,1.0584	- 0.0128,0.0129, 0.0354
BF P	1	rs28204 68	21967 3705	LYPLA L1	0.3 45	3.76E -11	3.46E- 21	0.9824,1.006 3,1.0364	- 0.0164,0.0066, 0.0328
	2	rs11282 49	16552 8624	GRB14	0.3 92	1.93E -09	2.32E- 18	0.9819,1.004 5,1.0279	- 0.0165,0.0039, 0.0275
	3	rs90039 9	15679 8732	CCNL1	0.3 97	1.82E -09	0.0001 21	1.0198,0.993 2,0.9746	0.0065,-4e- 04,-0.0138
	6	rs25236 25	31315 648	HLA-B	0.3 31	2.69E -10	0.0215	0.9852,1.007 1,1.0331	- 0.0049,0.0039, 0.0041
	16	rs62033 406	53824 226	FTO	0.4 11	2.15E -11	1.44E- 91	0.9806,0.999 1,1.0359	- 0.0367,0.0025, 0.0677
BM R	6	rs10456 362	28221 816	ZKSCA N4	0.1 61	1.48E -09	1.63E- 09	0.99,1.0252,1 .0064	- 0.0069,0.0163, 0.0186
	11	rs80083 564	27733 143	BDNF	0.1 36	1.15E -09	2.32E- 22	0.9895,1.027 3,1.0718	- 0.0092,0.0242, 0.0657
	12	rs78719 460	13339 5038	GOLGA 3	0.3 1	1.66E -09	1.92E- 12	0.984,1.0063, 1.0467	- 0.0108,0.0054,

								0.0289
16	rs14210 85	53800 954	FTO	0.4 04	8.95E -47	9.23E- 154	0.9561,1.000 8,1.0805	- 0.0469,0.0041, 0.09
18	rs47682 8	57852 587	MC4R	0.2 37	1.87E -20	1.35E- 148	0.9775,1.019 5,1.0716	- 0.0351,0.0388, 0.1125

Note: a) p values smaller than 2.0×10^{-9} are highlighted in pink; b) vQTLs with non-additive genetic effect on variance are highlighted in yellow.

(b) Testing for the variance effects of the BMI, WHR and FFR vQTLs on 1/HT², 1/HC and 1/FVC respectively.

vQTL test	SNP	vQTL p-value
BMI - 1/HT2	rs545608	4.42E-01
	rs6689335	2.00E-01
	rs62104180	4.31E-02
	rs6751993	2.97E-01
	rs10203386	6.71E-03
	rs1641155	6.74E-01
	rs1225053	1.90E-01
	rs10016841	3.98E-01
	rs12507026	9.08E-01
	rs34817112	2.08E-01
	rs3132947	3.90E-01
	rs987237	7.39E-01
	rs17150703	1.24E-01
	rs4132670	7.29E-01
	rs2049045	6.00E-01
	rs7132908	9.29E-01
	rs11057413	1.71E-01
	rs4072402	1.99E-01
	rs12716979	1.73E-01
	rs11642015	7.65E-01
	rs10871777	8.46E-01
	rs2238691	9.75E-01

rs459193	9.98E-01
rs6537292	5.82E-01
rs12374521	5.89E-01
rs56077333	5.11E-06
	rs459193 rs6537292 rs12374521 rs56077333

(c) GEI analyses with five environmental factors/covariates in the UKB.

Tra	СЦ	•			I	P values o	f GEI ana	lyses witł	1
11a ;+	р	SNP	BP	Nearest Gene	Say	Ago	D۸	CD	Smoki
п	ĸ				Sex	Age	PA	20	ng
FF	4	rs653729	145469		3.13E-	7.20E-	5.91E-	6.39E-	8.14E-
R	4	2	968	ппр	02	01	01	01	02
	-	rs123745	147836	FRV020	9.46E-	1.43E-	2.63E-	4.79E-	2.88E-
	5	21	880	FBXU38	02	01	01	02	04
	1 5	rs560773	788990	CUDNAC	2.36E-	2.52E-	9.88E-	3.02E-	4.55E-
	15	33	03	CHKNA3	02	02	01	04	25
BM	1	rs141466	240586	CDEM2	7.60E-	7.09E-	1.45E-	4.26E-	4.55E-
D	T	0	695	GREWZ	01	05	01	01	01
	6	rs937122	151885	CCDC170	9.81E-	7.05E-	8.33E-	7.69E-	1.28E-
	0	1	986	CCDC170	01	01	01	01	01
	6	rs302033	152008	ECD1	2.08E-	4.76E-	3.28E-	9.46E-	9.53E-
	0	2	924	ESKI	01	01	01	01	01
	7	rs457633	381537	CTADD2NI	2.85E-	9.08E-	1.17E-	4.58E-	4.45E-
	/	4	47	STARDSIL	01	02	01	01	01
	7	rs102548	120956	WINIT1	3.06E-	1.16E-	4.02E-	7.83E-	1.59E-
	/	25	440	VVIN I 10	04	07	01	01	03
	11	ma(02140	868846		1.07E-	2.75E-	5.74E-	4.58E-	7.51E-
	11	15005140	15	TMEM155	03	02	01	02	01
BW	2	rs133224	156795	CCNI 1	8.46E-	1.44E-	6.87E-	3.69E-	9.36E-
DVV	5	35	468	CCNET	02	01	01	01	01
BM	1	rs545608	177899	SFC16B	8.59E-	1.24E-	6.11E-	1.27E-	7.51E-
Ι	T	13545000	121	SECTOD	03	04	03	02	01
	1	rs668933	219628		6.65E-	1.90E-	3.15E-	1.13E-	7.38E-
	T	5	682		01	01	02	01	01
	C	rs621041	166002		2.75E-	5.36E-	2.52E-	2.07E-	1.48E-
	2	80	400003	ram130D	01	02	04	01	01
	2	rs675199	635864	TMEM18	7.08E-	1.01E-	1.49E-	9.67E-	2.06E-

	3			01	07	02	01	01
n	rs102033	251368		2.52E-	4.94E-	8.81E-	8.92E-	4.51E-
Z	86	66	ADC13	01	02	03	01	01
2	rs164115	589652	FANCI	8.94E-	4.64E-	9.82E-	3.09E-	3.73E-
Ζ	5	11	FANCL	01	01	01	01	01
2	rs122505	131642	CDNF 4	1.78E-	7.44E-	9.53E-	8.74E-	4.52E-
3	3	852	CPNE4	01	01	01	01	01
4	rs100168	202137		4.41E-	8.52E-	8.64E-	5.42E-	3.88E-
4	41	81	SLI I Z	01	01	03	03	03
4	rs125070	451813		1.59E-	6.19E-	6.40E-	1.46E-	5.21E-
4	26	34	GNPDAZ	01	02	02	01	01
6	rs348171	271766	DDCC16	9.93E-	1.91E-	1.52E-	9.24E-	9.21E-
0	12	28	PK3310	01	02	01	03	01
C	rs313294	321767	CDCM2	2.18E-	1.92E-	6.16E-	1.41E-	3.66E-
0	7	82	GP 3M 3	01	03	01	01	01
6	ma007227	508030		1.24E-	1.41E-	4.31E-	1.68E-	2.49E-
0	1596/23/	50	IFAP2D	01	02	01	01	02
0	rs171507	974579	МСДА	2.62E-	7.88E-	3.15E-	6.25E-	9.09E-
0	03	8	МЭКА	01	01	01	02	01
10	rs413267	114767	TCE71 2	3.03E-	5.72E-	1.73E-	6.84E-	2.36E-
10	0	771	ICF/LZ	01	01	03	04	01
11	rs204904	276942	DUNE	1.67E-	2.66E-	1.59E-	9.22E-	2.62E-
11	5	41	DDINF	01	01	02	01	01
10	rs713290	502631	οσπινόσ	2.73E-	2.94E-	1.36E-	2.15E-	5.88E-
12	8	48	DCDINOD	01	01	03	07	04
12	rs110574	124489	ZNF664-	1.02E-	2.03E-	6.54E-	5.81E-	9.57E-
12	13	162	FAM101A	01	01	02	03	01
16	rs407240	289372		9.25E-	1.30E-	1.82E-	2.72E-	3.58E-
10	2	59	KADEF 2	01	01	02	03	01
16	rs127169	310118	CTV1D	6.74E-	9.39E-	7.48E-	2.07E-	5.89E-
10	79	21	SIVID	03	01	03	01	01
16	rs116420	538024	ETO	5.01E-	2.35E-	1.28E-	1.64E-	9.24E-
10	15	94	ГIU	03	04	10	09	05
10	rs108717	578517	MCAD	4.63E-	3.72E-	3.52E-	1.41E-	3.22E-
10	77	63	мс4к	01	03	04	02	02
19	rs223869	461790	GIPR	4.83E-	7.04E-	5.95E-	1.74E-	6.53E-

		1	43		01	01	02	04	01
MC	1	rs109134	177913	CEC1(D	1.63E-	4.96E-	2.74E-	1.31E-	2.15E-
WC	1	69	519	SEC16B	01	03	02	01	01
	2	rs621041	466000		6.08E-	1.46E-	1.04E-	4.77E-	5.19E-
	2	80	466003	FAM150B	02	01	04	01	01
	2	rs134121	(52245		4.87E-	1.88E-	3.70E-	7.16E-	3.15E-
	Ζ	94	653245	TMEM18	01	07	02	01	01
	2	rs764997	123922		6.35E-	1.49E-	8.87E-	7.91E-	9.55E-
	3	0	72	PPARG	01	01	02	01	01
	4	rs125070	451813		2.12E-	2.10E-	4.08E-	6.70E-	8.13E-
	4	26	34	GNYDAZ	01	02	01	02	01
	C	rs131987	265820	٨ ٦٣٠٩	1.52E-	1.50E-	3.11E-	2.45E-	5.51E-
	0	16	35	ARIT	01	04	02	03	01
	C	rs106207	321480		2.30E-	3.46E-	2.32E-	3.13E-	1.96E-
	0	0	31	KNF5	01	05	01	01	01
	C	rs447233	347697		2.03E-	6.15E-	3.14E-	5.56E-	4.73E-
	0	7	65	UHKFIBPI	01	01	02	03	01
	C	ma007007	508030		2.52E-	9.32E-	5.61E-	2.19E-	3.32E-
	6	rs98/23/	50	IFAP2B	02	03	01	01	02
	7	rs126672	130449		2.61E-	6.30E-	6.99E-	3.50E-	8.05E-
	/	51	458	KLF14	01	01	01	01	01
	10	rs713337	124409	CCDCO2	3.59E-	1.45E-	7.05E-	3.62E-	6.79E-
	12	8	502	UUUU92	03	01	01	03	01
	16	rs805689	288974	ለጥጉጋ ለ 1	8.75E-	1.52E-	3.93E-	4.24E-	2.10E-
	10	0	52	ATP2A1	01	01	02	03	01
	16	rs348985	310256	ርጥህ1 ቦ	5.92E-	7.08E-	1.69E-	2.92E-	9.87E-
	10	35	41	21YIR	03	01	02	01	01
	16	rs142108	538009	ETTO	3.04E-	2.17E-	1.44E-	2.84E-	1.10E-
	10	5	54	ГIU	02	04	07	08	02
	10	rs111522	578529	MCAD	2.80E-	1.36E-	2.21E-	3.39E-	2.14E-
	10	13	48	МС4К	02	02	03	02	01
	10	rs180043	461813	CIDD	1.84E-	4.59E-	1.62E-	9.50E-	1.81E-
	19	7	92	GIPK	01	01	01	04	01
	1	rs668559	203516	ODTC	6.22E-	8.84E-	3.48E-	7.42E-	3.80E-
НС	T	3	075	UPIC	01	01	01	02	01
	1	rs260509	219643	LYPLAL1	8.00E-	8.14E-	5.37E-	4.52E-	9.48E-

		8	649		03	01	02	01	01
	2	rs621041	466000		3.95E-	2.89E-	2.27E-	4.70E-	1.62E-
	Ζ	80	466003	FAM150B	01	01	05	02	01
	2	rs675199	(250(4		6.50E-	2.35E-	1.87E-	5.09E-	3.11E-
	2	3	635864	TMEM18	01	04	02	01	01
	0	rs102005	251304		2.35E-	1.73E-	3.57E-	7.90E-	7.74E-
	2	66	62	ADCY3	01	01	02	01	01
	<i>.</i>	rs341587	263365		4.31E-	1.05E-	1.14E-	1.60E-	9.93E-
	6	69	72	BTN3A2	01	02	02	02	01
	C	rs313294	321767	CDCMO	9.79E-	4.23E-	2.53E-	3.71E-	7.46E-
	6	7	82	GPSM3	01	03	01	01	02
	ſ	rs728917	508582		2.32E-	2.19E-	5.21E-	8.67E-	1.67E-
	0	17	35	TFAPZB	01	02	01	01	01
	<i>.</i>	rs141783	127439		5.75E-	5.59E-	5.95E-	8.08E-	6.84E-
(0	576	897	KSPU3	01	01	02	02	01
7	7	rs177895	130445		6.09E-	4.28E-	5.89E-	1.36E-	2.73E-
	/	06	574	NLF14	05	01	02	01	01
	12	rs108465	124415	CCDC02	6.97E-	1.10E-	4.89E-	1.93E-	6.48E-
	12	80	453	660672	02	01	01	02	01
	16	rs805689	288974	ለ ጥ ወ ጋ ለ 1	7.53E-	2.66E-	1.68E-	2.05E-	5.89E-
	10	0	52		01	01	02	02	01
	16	rs348985	310256	STX1 R	1.60E-	4.20E-	1.62E-	1.94E-	2.77E-
	10	35	41	JIAID	02	01	02	01	01
	16	rs142108	538009	FTO	1.18E-	2.05E-	5.32E-	2.17E-	1.94E-
	10	5	54	PIO	01	03	07	06	04
	18	rs111522	578529	MC4R	2.38E-	2.19E-	9.80E-	1.41E-	6.68E-
	10	13	48	мстк	01	02	04	02	03
	19	rs223869	461790	CIPR	8.71E-	9.12E-	2.66E-	2.64E-	2.85E-
	17	1	43	un K	02	01	01	04	01
WH	۱ 5	rs459193	558067	C5orf67	9.25E-	4.82E-	1.92E-	3.48E-	6.67E-
R			51	6301107	02	01	01	04	01
BF	1	rs282046	046 219673	8.76E-	1.19E-	1.60E-	8.66E-	2.40E-	
Р	Ŧ	8	705		01	01	02	02	01
	2	rs112824	165528	GRR14	3.18E-	2.91E-	3.55E-	3.41E-	5.58E-
	4	9	624	UIDIT	01	02	01	04	01
	3	rs900399	156798	CCNL1	1.04E-	2.63E-	2.15E-	1.13E-	1.64E-

			732		05	01	01	02	02
	6	rs252362	313156	HLA-B	2.66E-	2.87E-	1.35E-	6.76E-	6.38E-
		5	48		01	01	01	01	01
	16	rs620334	538242	FTO	1.14E-	2.47E-	4.43E-	3.52E-	1.02E-
	10	06	26	PTO	02	04	03	02	01
BM	6	rs104563	282218	ZKSCAN4	8.90E-	8.38E-	6.68E-	1.60E-	9.13E-
R	0	62	16		01	03	01	01	01
	11	rs800835	277331	BDNE	4.20E-	1.69E-	1.00E-	5.22E-	9.89E-
		64	43	DDM	01	02	01	01	01
	12	rs787194	133395		3.41E-	8.69E-	3.04E-	9.40E-	6.67E-
		60	038	GOLGAS	01	01	01	01	01
	16	rs142108	538009	ETTO	2.07E-	2.60E-	1.52E-	1.45E-	1.54E-
		5	54	110	01	07	06	07	03
	18	rs476828	578525	MC4R	1.20E-	1.22E-	9.98E-	6.47E-	1.62E-
	10		87	MC4K	01	03	03	02	02

Note: p values smaller than 1.33×10^{-4} are highlighted in pink.

Table S3. GEI examples.

		Effects	Effect size (Standard error)			P values			
Phonotymo	Top vQTL	nev	er	ever	νΩTI	OTI		GEI test	
rnenotype	SNP	smoker	rs (n= s	mokers (n=	= apolycic	UIL analw	GE		
		188,8	860)	160,488)	analysis	analy:	.S		
FED	rc5607722	0.01	05	-0.0453	1 00F 1	1 211E	06 15	SE 25	
ГГК	122007733	3 (0.00	35)	(0.0042)		+ 2.11L-	4.5	4.55E-25	
(b) GEI effect between the WNT16-CPED1 locus and age on BMD									
		Effect size (Standard error)			P values				
	-	Age	Age	Age	Age				
	Του νΟΤΙ	group 1:	group 2:	group 3	group 4:				
'henotype	SNP	40-49	50-59	60-69	70-74	vQTL	QTL	GEI	
		years	years	years	years	analysis	analysis	test	
		(<i>n</i> =	(<i>n</i> =	(<i>n</i> =	(<i>n</i> =				
		59,734)	108,736)	156,173) 23,250)				
RMD	rs10254825	0.1448	0.1650	0.1907	0.1765	2.01E-	0	1.16E	
DMD		(0.0081)	(0.0059)	(0.0050)) (0.0119)	45	0	07	
(c) Associations of <i>FTO</i> locus with obesity-related traits stratified by physical activity (PA) levels									
		Eff	Effect size (Standard error)				P values		
	TonuOTI	Low PA	Into	madiata	High PA				
Phenotype	SNP	group	DΔ	group	group	vQTL	QTL	GEI	
	SNP	(<i>n</i> =	(n - ⁻	1 /1 5 8 8 9 1	(<i>n</i> =	analysis	analysis	test	
		103,374)	145,0095	97,506)				
BMI	rc11642015	0.1018	0	.0715	0.0609	1.73E-	7.43E-	1.28E-	
DMI	1311042013	(0.0049)) (0	.0037)	(0.0041)	73	217	10	
WC	rs1421085	0.0858	0	.0652	0.0524	3.27E-	3.21E-	1.44E-	
WC		(0.0048)) (0	.0037)	(0.0042)	52	166	07	
нс	rs1421085	0.0825	0	.0623	0.0505	1.65E-	2.05E-	5.32E-	
IIC		(0.0049)) (0	.0037)	(0.0042)	48	152	07	
DMD	rc142100E	0.0842	0	.0608	0.0531	8.95E-	9.23E-	1.52E-	
DMK	131421005	(0.0049)) (0	.0037)	(0.0043)	47	154	06	
(d) Associa	tions of <i>FTO</i> lo	ocus with ol	pesity-rel	ated traits s	tratified by	sedentary	behaviour	(SB)	
levels									
Phenotype	Top vQTL	Eff	ect size (S	Standard er	ror)		P values		

(a) GEI effect between the CHRNA5-A3-B4 locus and smoking on FFR

	SNP	SB group 1: 0-5 hours (<i>n</i> = 244,215)	SB group 2: 6-11 hours (<i>n</i> = 89,712)	SB group 3: 12-17 hours (<i>n</i> = 5,445)	vQTL analysis	QTL analysis	GEI test
BMI	rs11642015	0.0694	0.1001	0.1085	1.73E-	7.43E-	1.64E-
MC	rs1421085	0.0593	0.0879	0.1089	73 3.27E-	217 3.21E-	09 2.84E-
WC		(0.0028)	(0.0050)	(0.0223)	52	166	08
нс	rs1421085	0.0577	0.0815	0.1199	1.65E-	2.05E-	2.17E-
IIC		(0.0028)	(0.0052)	(0.0230)	48	152	06
BMR	rs1421085	0.0576	0.0849	0.1024	8.95E-	9.23E-	1.45E-
		(0.0028)	(0.0052)	(0.0233)	47	154	07